In the whole series, patients with SOX2-positive meningiomas had PFS and OS significantly lower than those with SOX2-negative meningiomas (median PFS 38.4 months in SOX2-positive meningiomas vs not reached in SOX2-negative tumors; p < 0.0001, log-rank test; median OS 173.9 months in SOX2-positive vs not reached in SOX2-negative tumors; p = 0.0001 Log-rank test; Figure 4A,B). This evidence concerns the gene SOX2 and meningioma.